Bryan, TX, United States of America

Ken Carson

This inventor holds 2 USPTO granted patents. Top assignees: Texas A&M University System, University of California. Active years: 2014-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ken Carson. Retrieved from https://idiyas.com/inventor/ken-carson-4frqjcq3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ken Carson: Inventor in Biomedical Research

Introduction

Ken Carson is an inventor associated with Bryan, Texas. His patent work includes research into protein-based microencapsulation and approaches to inhibiting amyloid formation and neurotoxicity. The supplied information lists 2 patents.

Latest Patents

“Use of Vitelline Protein B as a Microencapsulating Additive” describes compositions and methods using an encapsulation additive containing about 0.1 to 30 percent isolated and purified vitelline protein B. The additive is intended to support mixed and extended-release formulations.

“HSP20 Inhibits Amyloidogenesis and Neurotoxicity” describes compositions and methods using portions of an isolated and purified α-crystallin polypeptide. The polypeptide includes one or more β-pleated sheets and is intended to prevent amyloidogenesis and neurotoxicity.

Career Highlights

The supplied information associates Carson with the Texas A&M University System and the University of California. His listed patent topics reflect work involving protein applications and potential biomedical uses.

Collaborations

Carson’s listed coworkers include Allison R. Ficht and John Herbert Waite, whose names are associated with the patent information provided.

Conclusion

Ken Carson’s listed inventions explore protein-based formulations and strategies aimed at addressing amyloidogenesis and neurotoxicity, reflecting the biomedical focus of his patent work.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…